Trial-Results center  
Clinical trial results database Feedback    Home


Related trials

ZEST AMI (vs SES), 2009 - zotarolimus ES vs sirolimus ES

TRIANA, 2009 - primary ballon angioplasty vs tenecteplase

DEBATER (SES vs BMS), 2009 - sirolimus ES vs bare-metal stent

NORDISTEMI, 2009 - thrombolysis + angioplasty vs immediate thrombolysis

Juwana, 2009 - sirolimus ES vs paclitaxel ES

ZEST AMI (vs PES), 2009 - zotarolimus ES vs paclitaxel ES

PASEO, 2009 - drug ES vs bare-metal stent

CARESS, 2008 - thrombolysis + angioplasty vs immediate thrombolysis

HORIZONS-AMI Stent, 2008 - paclitaxel ES vs bare-metal stent

MISSION, 2008 - sirolimus ES vs bare-metal stent

DEDICATION, 2008 - drug ES vs bare-metal stent

Díaz de la Llera, 2007 - sirolimus ES vs bare-metal stent

SESAMI, 2007 - sirolimus ES vs bare-metal stent

TYPHOON, 2006 - sirolimus ES vs bare-metal stent

PROSIT, 2006 - sirolimus ES vs paclitaxel ES

HAAMU-STENT, 2006 - paclitaxel ES vs bare-metal stent

PASSION, 2006 - paclitaxel ES vs bare-metal stent

WEST, 2006 - systematic PCI (+stent) vs no systematic PCI

CAPITAL AMI, 2005 - thrombolysis + angioplasty vs immediate thrombolysis

Di Lorenzo et al., 2005 - sirolimus ES vs paclitaxel ES

ZWOLLE 6, 2005 - primary stenting vs ballon angioplasty

CAPITAL AMI, 2005 - systematic PCI (+stent) vs no systematic PCI

senior PAMI, 2005 - primary PCI vs thrombolytic therapy

STOPAMI 3, 2004 - primary stenting vs ballon angioplasty

GRACIA-1, 2004 - systematic PCI (+stent) vs no systematic PCI



See also:

  • All acute myocardial infarction clinical trials
  • All clinical trials of PCI
  • All clinical trials of primary ballon angioplasty
    		•  

    Zijlstra study, 1997

    Treatments

    Studied treatment primary PTCA
    Control treatment streptokinase 1.5 M IU over 1h
    Concomittant treatment aspirin, heparin IV
    Treatments description
    Delay from symptoms 6h (or between 6-24h) 

    Patients

    Patients atients with acute myocardial infarction
    Inclusion criteria Low risk patients symptoms of myocardial infraction for >30min, within 6h of symptom onset or between 6 and 24h if there were signs and symptoms of ongoing ischemia with >=0.1mV ST segment in more than 2 leads
    Exclusion criteria life expectency <6 months; high risk: contraindication to thrombolysis, Killip>=2, ECG evidence of anterior wall infarction
    Baseline characteristics
    anterior MI 0% 
    Delay to treatment (PTCA vs thr) 38 min 
    Previous MI 19% 
    Killip>=2 0% 
    % female 23% 
    mean age 61 y 

    Method and design

    Randomized effectives 45 / 50 (studied vs. control)
    Design Parallel groups
    Blinding open
    Follow-up duration 6 months
    Lost to follow-up ND
    Number of centre single center
    Geographic area The Netherland
    Primary endpoint death, nonfatal stroke or reinfarcti
    Withdrawals (T1/T0) ND /


    Results

    No results available for this trial - no clinical endpoint reported



    Reference(s)

    Trials register # NA
    • Zijlstra F, Beukema WP, van 't Hof AW, Liem A, Reiffers S, Hoorntje JC, Suryapranata H, de Boer MJ. Randomized comparison of primary coronary angioplasty with thrombolytic therapy in low risk patients with acute myocardial infarction.. J Am Coll Cardiol 1997;29:908-12
      Pubmed | Hubmed | Fulltext

    (c) 2004-2010 TrialResults-center - All Rights Reserved

    Tweet this  |  notify a friend